>MedPage Today The JAK1 inhibitor upadacitinib Rinvoq was superior to placebo in inducing endoscopic remission in refractory Crohn's disease CD patients the phase II randomized CELEST trial showed.Juli&225;n Pan&233;s MD PhD of...
↧